Lina is a global leader with 25 years of experience in the pharmaceutical industry spanning the European and U.S. markets, as well as broader international operations. Driven by her belief in always going the extra mile, Lina has maintained a steadfast focus on the individuals, families, and communities that benefit from the therapies her teams develop and bring to market.

Lina values authenticity and seeks to develop teams with diverse backgrounds, capabilities, and experiences that come together towards a common goal to achieve success. Her dedication to patients and drive for excellence has been the foundation for delivering competitor outpacing performance on large primary care brands to highly specialized rare disease therapies in CNS, cardiovascular, renal and metabolic diseases.

In her role at Otsuka, Lina will provide strategic leadership of the Nephrology and Immunology business, partnering closely with cross-functional teams, to ensure the successful development, launch, and commercialization of Otsuka’s rare disease portfolio.

Prior to joining Otsuka, Lina held several commercial executive leadership roles at Astra Zeneca for 14 years spanning multiple brands that treat kidney and cardiovascular diseases. Most recently, she built out an organization and led the launch of a treatment for the rare disease hereditary ATTR amyloidosis. Lina has also held brand and sales leadership roles at Eli Lilly in Europe spanning multiple disease states, including CNS.

Lina holds a BA in Business Administration from Lund University in Sweden.

Our goal at Otsuka is to ensure that every patient we serve receives the highest quality care and support possible. There will always be challenges and setbacks, but Otsuka-people have a relentless determination to find solutions and never give up on the patients counting on us.